Pfizer presented detailed data supporting monthly dosing for berobenatide, its long-acting GLP-1 obesity drug acquired from Metsera. Results from VESPER-3 described a treatment transition from weekly dosing to monthly dosing, with weight loss continuing beyond the weekly-to-monthly switch at up to 28 weeks. The update reported that participants who stayed on therapy had weight loss up to 12.1% by 28 weeks. Pfizer emphasized that the rate of weight loss did not appear to plateau by that time point, positioning monthly administration as a practical differentiator. Competitive implications depend on comparative effectiveness against weekly injectables and on whether monthly dosing sustains efficacy at longer durations. The next readout milestones will likely focus on durability, tolerability, and head-to-head differentiation versus the class.